about
Epigenetic treatment of solid tumours: a review of clinical trialsMethyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factorMicroRNA: basic mechanisms and transcriptional regulatory networks for cell fate determinationValproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cellsFusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemiaA minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesisStage-specific modulation of skeletal myogenesis by inhibitors of nuclear deacetylases.Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein.MBD3, a component of the NuRD complex, facilitates chromatin alteration and deposition of epigenetic marks.PML nuclear body disruption impairs DNA double-strand break sensing and repair in APL.Epigenetic plasticity of chromatin in embryonic and hematopoietic stem/progenitor cells: therapeutic potential of cell reprogramming.Argonaute 2 sustains the gene expression program driving human monocytic differentiation of acute myeloid leukemia cells.A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms.Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents.RARs and microRNAs.Myc-binding-site recognition in the human genome is determined by chromatin context.Molecular signature of retinoic acid treatment in acute promyelocytic leukemia.Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo.Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status.Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL.Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid signalling.Expression of SMRTbeta promotes ligand-induced activation of mutated and wild-type retinoid receptors.Estrogen receptor expression activates the transcriptional and growth-inhibitory response to retinoids without enhanced retinoic acid receptor alpha expression.Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wild-type retinoid receptors in retinoid-resistant acute promyelocytic leukemia cell lines.Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the pml/RAR alpha protein.A novel epigenetic AML1-ETO/THAP10/miR-383 mini-circuitry contributes to t(8;21) leukaemogenesis.Transcriptional fine-tuning of microRNA-223 levels directs lineage choice of human hematopoietic progenitors.Transcriptional targeting by microRNA-polycomb complexes: a novel route in cell fate determination.A transcriptome-wide approach reveals the key contribution of NFI-A in promoting erythroid differentiation of human CD34(+) progenitors and CML cells.Polycombs and microRNA-223 regulate human granulopoiesis by transcriptional control of target gene expression.Complete remission through blast cell differentiation in PLZF/RARalpha-positive acute promyelocytic leukemia: in vitro and in vivo studies.Increased cholesterol sulfate and cholesterol sulfotransferase activity in relation to the multi-step process of differentiation in human epidermal keratinocytes.Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells.NFI-A directs the fate of hematopoietic progenitors to the erythroid or granulocytic lineage and controls beta-globin and G-CSF receptor expression.Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells.The integrity of the charged pocket in the BTB/POZ domain is essential for the phenotype induced by the leukemia-associated t(11;17) fusion protein PLZF/RARalpha.Epigenetic role of miRNAs in normal and leukemic hematopoiesis.Down-stream regions of the POZ-domain influence the interaction of the t(11;17)-associated PLZF/RARalpha fusion protein with the histone-deacetylase recruiting co-repressor complex.Dielectric spectroscopy of blood cells suspensions: study on geometrical structure of biological cells.Homeobox 1.3 expression: induction by retinoic acid in human bronchial fibroblasts.
P50
Q26773803-5A7F6426-EC9C-443B-BF9E-723AFCF93813Q28217975-4FBCCB73-0A56-41DE-9753-E0D55CDBA23EQ28283112-B2C4F113-5CAA-400C-9FF3-AEB7326900A1Q28366303-E2397CCA-DF15-498C-BEC5-69E0DEDB0DFDQ29616211-E5B3FCE1-FFF4-4D26-81A9-EDAFFF9D3AE3Q29619201-9D7DE2D1-1732-4D50-B86B-0FA5AAB6DCFDQ34065460-B66FE649-7D59-4F3D-AE99-B92997E33439Q34712578-2DCDE1CC-25FE-4F49-8FF9-42F211A5062FQ36898949-BA32F203-2F8F-405C-9744-5DA4C0ACFF3FQ37151474-3A92975C-C465-4ABD-9552-D5ACE94A35CDQ37189326-42CA7F2A-96BB-4FCD-A95C-AF2FF0438471Q37357102-111B5861-EDE4-49BB-B370-8245929D2FEFQ37623156-E3481321-89B8-4181-B13D-52804E741194Q38120368-D56DB3CE-C9E4-4003-9D02-75DAEC10BAB6Q38223067-31D91A43-5FD6-47BB-8D82-B3AE82C934C8Q38312447-F4C38D88-EFA5-4822-9FFB-BBB395071C50Q38329965-9212F0A5-486F-4339-B12A-1FB7B3EC92C5Q38331050-8815D070-E1FF-4C75-ABA6-C71097792611Q39940410-64343210-002A-47F9-9D97-F95048447041Q39998537-D33E4066-0DFC-4411-90FC-18C6963AE409Q40023123-7A9748B9-F4B7-4689-AC1F-1C3C27E3EDF3Q40524110-A526E307-D899-4DB5-AEDE-0B36282057FDQ40993322-0AE15670-F6AF-4A40-86A1-BFBAA7579566Q41164437-EF3D2BCD-9074-472C-9C59-5CB85DA7BDC0Q41529062-B15FC773-193B-40BC-96C1-E366DE1A3357Q41569195-F2134285-61B2-460E-B02E-FC738FD549B4Q41870129-52E23318-9D5F-4272-8E9C-DAE9989A8DA3Q42131035-FECC3C2F-660F-49A1-8C52-92DCDFF6C5B9Q43081268-17D32A52-41C7-4725-B16F-704ED4C4C7A8Q43857650-12B77A3A-6088-4B0F-A6C2-B404CD3DD701Q44072008-B0A1A976-2824-4A1D-996C-E5D69397583BQ45011356-3D771DF6-EDD9-46DA-92CD-02C9E9239383Q45285591-7E8074DE-2978-479B-8ED1-AA4E261E703CQ45960681-FF8718F9-C2D2-405A-B953-A228EA85A698Q46252694-030E6FC8-8AFA-449A-8887-B9A07E297D18Q46604644-7CA7A43D-F06A-4AD3-8F6A-4CE217FD72BAQ46608275-2151746D-5D34-47F8-8733-40BC2FFDFEA7Q50500896-0E966404-9778-4E68-A3FA-905D2542BBF3Q50673108-591A5688-08D7-4C05-857D-19704E484CD8Q52230768-C19D1F26-9258-4391-BECE-DEBF0361D937
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0001-9341-0188
@en
name
Clara Nervi
@ast
Clara Nervi
@en
Clara Nervi
@es
Clara Nervi
@nl
type
label
Clara Nervi
@ast
Clara Nervi
@en
Clara Nervi
@es
Clara Nervi
@nl
prefLabel
Clara Nervi
@ast
Clara Nervi
@en
Clara Nervi
@es
Clara Nervi
@nl
P106
P1153
7006140509
P31
P496
0000-0001-9341-0188